IDEXX Laboratories Net Worth
IDEXX Laboratories Net Worth Breakdown | IDXX |
IDEXX Laboratories Net Worth Analysis
IDEXX Laboratories' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including IDEXX Laboratories' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of IDEXX Laboratories' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform IDEXX Laboratories' net worth analysis. One common approach is to calculate IDEXX Laboratories' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares IDEXX Laboratories' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing IDEXX Laboratories' net worth. This approach calculates the present value of IDEXX Laboratories' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of IDEXX Laboratories' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate IDEXX Laboratories' net worth. This involves comparing IDEXX Laboratories' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into IDEXX Laboratories' net worth relative to its peers.
Enterprise Value |
|
To determine if IDEXX Laboratories is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding IDEXX Laboratories' net worth research are outlined below:
| IDEXX Laboratories generated a negative expected return over the last 90 days | |
| IDEXX Laboratories is unlikely to experience financial distress in the next 2 years | |
| IDEXX Laboratories currently holds 1.07 B in liabilities with Debt to Equity (D/E) ratio of 3.28, implying the company greatly relies on financing operations through barrowing. IDEXX Laboratories has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about IDEXX Laboratories' use of debt, we should always consider it together with its cash and equity. | |
| Over 94.0% of IDEXX Laboratories shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 3,382 Shares of IDEXX Laboratories, Inc. |
IDEXX Laboratories Quarterly Good Will |
|
IDEXX Laboratories uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in IDEXX Laboratories. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to IDEXX Laboratories' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know IDEXX Laboratories' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as IDEXX Laboratories is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IDEXX Laboratories backward and forwards among themselves. IDEXX Laboratories' institutional investor refers to the entity that pools money to purchase IDEXX Laboratories' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blair William & Co | 2024-06-30 | 1.2 M | Brown Advisory Holdings Inc | 2024-09-30 | 1.1 M | Norges Bank | 2024-06-30 | 994.4 K | Fundsmith Investment Services Ltd. | 2024-09-30 | 865 K | Goldman Sachs Group Inc | 2024-06-30 | 815.4 K | Legal & General Group Plc | 2024-06-30 | 777.3 K | Northern Trust Corp | 2024-09-30 | 769.5 K | Jpmorgan Chase & Co | 2024-06-30 | 756.2 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 751.9 K | Vanguard Group Inc | 2024-09-30 | 9.7 M | Blackrock Inc | 2024-06-30 | 9.6 M |
Follow IDEXX Laboratories' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 34.17 B.Market Cap |
|
Project IDEXX Laboratories' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.30 | 0.32 | |
| Return On Capital Employed | 0.48 | 0.26 | |
| Return On Assets | 0.26 | 0.27 | |
| Return On Equity | 0.57 | 0.60 |
When accessing IDEXX Laboratories' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures IDEXX Laboratories' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of IDEXX Laboratories' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in IDEXX Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IDEXX Laboratories. Check IDEXX Laboratories' Beneish M Score to see the likelihood of IDEXX Laboratories' management manipulating its earnings.
Evaluate IDEXX Laboratories' management efficiency
IDEXX Laboratories has return on total asset (ROA) of 0.2279 % which means that it generated a profit of $0.2279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5942 %, meaning that it created $0.5942 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 17.87 | 18.77 | |
| Tangible Book Value Per Share | 12.45 | 13.07 | |
| Enterprise Value Over EBITDA | 38.37 | 19.30 | |
| Price Book Value Ratio | 31.06 | 32.61 | |
| Enterprise Value Multiple | 38.37 | 19.30 | |
| Price Fair Value | 31.06 | 32.61 | |
| Enterprise Value | 7.2 B | 7.6 B |
The management strategies employed by IDEXX Laboratories' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Enterprise Value Revenue 9.0672 | Revenue 3.8 B | Quarterly Revenue Growth 0.066 | Revenue Per Share 46.447 | Return On Equity 0.5942 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IDEXX Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on IDEXX Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases IDEXX Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
IDEXX Laboratories Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 9th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 31st of May 2024 Other Reports | ViewVerify |
IDEXX Laboratories Earnings per Share Projection vs Actual
IDEXX Laboratories Corporate Executives
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian McKeon | CFO, Principal Accounting Officer, Executive VP and Treasurer | Profile | |
| Nimrata PE | Sector Strategy | Profile | |
| Martin Smith | Executive CTO | Profile |
Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.